GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Catalent Inc (NYSE:CTLT) » Definitions » Cyclically Adjusted PS Ratio

Catalent (Catalent) Cyclically Adjusted PS Ratio : 2.42 (As of May. 16, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Catalent Cyclically Adjusted PS Ratio?

As of today (2024-05-16), Catalent's current share price is $55.61. Catalent's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $23.00. Catalent's Cyclically Adjusted PS Ratio for today is 2.42.

The historical rank and industry rank for Catalent's Cyclically Adjusted PS Ratio or its related term are showing as below:

CTLT' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.46   Med: 2.45   Max: 6.4
Current: 2.41

During the past years, Catalent's highest Cyclically Adjusted PS Ratio was 6.40. The lowest was 1.46. And the median was 2.45.

CTLT's Cyclically Adjusted PS Ratio is ranked worse than
54.62% of 747 companies
in the Drug Manufacturers industry
Industry Median: 2.17 vs CTLT: 2.41

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Catalent's adjusted revenue per share data for the three months ended in Mar. 2024 was $5.901. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $23.00 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Catalent Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Catalent's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Catalent Cyclically Adjusted PS Ratio Chart

Catalent Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 4.96 1.92

Catalent Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.94 1.92 1.99 1.96 2.45

Competitive Comparison of Catalent's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Catalent's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Catalent's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Catalent's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Catalent's Cyclically Adjusted PS Ratio falls into.



Catalent Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Catalent's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=55.61/23
=2.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Catalent's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Catalent's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=5.901/129.4194*129.4194
=5.901

Current CPI (Mar. 2024) = 129.4194.

Catalent Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 4.430 100.560 5.701
201409 3.964 100.428 5.108
201412 3.619 99.070 4.728
201503 3.537 99.621 4.595
201506 4.036 100.684 5.188
201509 3.352 100.392 4.321
201512 3.615 99.792 4.688
201603 3.482 100.470 4.485
201606 4.235 101.688 5.390
201609 3.502 101.861 4.449
201612 3.826 101.863 4.861
201703 4.200 102.862 5.284
201706 4.839 103.349 6.060
201709 4.256 104.136 5.289
201712 4.559 104.011 5.673
201803 4.647 105.290 5.712
201806 5.072 106.317 6.174
201809 3.882 106.507 4.717
201812 4.248 105.998 5.187
201903 4.208 107.251 5.078
201906 4.929 108.070 5.903
201909 4.563 108.329 5.451
201912 4.885 108.420 5.831
202003 4.968 108.902 5.904
202006 5.939 108.767 7.067
202009 5.096 109.815 6.006
202012 5.391 109.897 6.349
202103 6.122 111.754 7.090
202106 6.867 114.631 7.753
202109 5.959 115.734 6.664
202112 6.805 117.630 7.487
202203 7.033 121.301 7.504
202206 7.110 125.017 7.360
202209 5.646 125.227 5.835
202212 6.348 125.222 6.561
202303 5.729 127.348 5.822
202306 5.734 128.729 5.765
202309 5.425 129.860 5.407
202312 5.626 129.419 5.626
202403 5.901 129.419 5.901

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Catalent  (NYSE:CTLT) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Catalent Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Catalent's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Catalent (Catalent) Business Description

Traded in Other Exchanges
Address
14 Schoolhouse Road, Somerset, NJ, USA, 08873
Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents.
Executives
David Mcerlane officer: Group President, Biologics C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Steven Barg director ELLIOTT MANAGEMENT CORPORATION, 40 WEST 57TH STREET, NEW YORK NY 10019
Michelle R Ryan director 214 PARK BLVD S, VENICE FL 34285
John J Greisch director C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Stephanie Okey director C/O ALBIREO PHARMA, INC., 10 POST OFFICE SQUARE, SUITE 502 SOUTH, BOSTON MA 02109
Frank A Damelio director C/O PFIZER INC., 235 EAST 42ND ST., NEW YORK NY 10017
Aristippos Gennadios officer: See Remarks C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Thomas W Hawkeswood officer: Pres. Pharma Prod Delivery Div C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Patricia Hunt officer: Pres. Consumer Health Div C/O CATALENT, 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Ricky Hopson officer: VP, Chief Accounting Officer CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Lorenzo Carletti officer: SVP Global Ops Small Molecule C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Ricardo Pravda officer: SVP, Human Resources C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Alessandro Maselli officer: See remarks C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Charles Lickfold officer: SVP, CIO C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Scott Gunther officer: See Remarks C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873

Catalent (Catalent) Headlines